Brief: Kamada Announces Top-Line Results From Phase 1/2 Trial Of Its Plasma-Derived Hyperimmune Globulin Treatment For Covid-19

Kamada

31/03/2021 11:32

March 31 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA ANNOUNCES TOP-LINE RESULTS FROM ITS PHASE 1/2
CLINICAL
TRIAL OF ITS PLASMA-DERIVED HYPERIMMUNE GLOBULIN (IGG) TREATMENT
FOR CORONAVIRUS DISEASE (COVID-19)
    * KAMADA LTD - NO INFUSION-RELATED REACTIONS OR ADVERSE
EVENTS
CONSIDERED RELATED TO STUDY DRUG WERE OBSERVED
    * KAMADA LTD - PRELIMINARY RESULTS DEMONSTRATED THAT IGG
LEVEL
INCREASE WAS ASSOCIATED WITH ENHANCED NEUTRALIZATION ACTIVITY
    * KAMADA LTD - ONE PATIENT DIED ON DAY 37 POST-TREATMENT DUE
TO
COMPLICATIONS FROM COVID-19
    * KAMADA LTD - THERE WERE TWO SERIOUS ADVERSE EVENTS IN
STUDY,
BOTH WERE CONSIDERED NOT RELATED TO STUDY DRUG
    * KAMADA LTD - CONTINUE TO SUPPLY PRODUCT TO IMOH FOR
TREATMENT OF
COVID-19 PATIENTS IN ISRAEL
    * KAMADA LTD - INITIAL ORDER FROM IMOH EXPECTED TO GENERATE
APPROXIMATELY $3.4 MILLION IN REVENUE FOR KAMADA
    * KAMADA LTD - SCALED UP MANUFACTURING WILL SUPPORT
POTENTIAL
EXPANSION OF IMOH SUPPLY AGREEMENT, POSSIBLE DEMAND FROM
ADDITIONAL INTERNATIONAL MARKETS

Source text for Eikon:  ID:nGNX99tbN5 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))